Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer’s disease and mild cognitive impairment

Table 3 Significant correlations between plasma total apoE levels and CSF AD biomarkers

Race/ethnicity	Studied subjects	Sample number (n)	CSF markers (pg/mL)	APOE genotype unaccounted for		APOE genotype accounted for
Race/ethnicity	Studied subjects	Sample number (n)	CSF markers (pg/mL)	Correlation (95% CI)	p-value	Correlation (95% CI)	p-value
Whole cohort	All	122	t-tau/Αβ₄₂	ρ = − 0.184 (− 0.355, − 0.001)	0.042	r (119) = − 0.122 (− 0.293, − 0.056)	0.183
	Controls	51	Αβ₄₂	r = 0.307 (0.034, 0.537)	0.029	r (48) = 0.287 (0.012, 0.521)	0.044
	Controls	51	t-tau/Αβ₄₂	ρ = − 0.346 (− 0.567, − 0.078)	0.013	r (48) = − 0.292 (− 0.525, − 0.018)	0.040
	MCI	47	t-tau/Αβ₄₂	ρ = − 0.295 (− 0.536, − 0.009)	0.044	r (44) = − 0.225 (− 0.481, 0.066)	0.132
B/AAs	Controls	22	Aβ₄₀	r = 0.481 (0.075, 0.750)	0.023	r (19) = 0.478 (0.071, 0.749)	0.028
		23	Αβ₄₂	r = 0.460 (0.059, 0.733)	0.027	r (20) = 0.459 (0.058, 0.733)	0.032
		23	t-tau	ρ = 0.608 (0.262, 0.815)	0.002	r (20) = 0.625 (0.287, 0.824)	0.002
	AD	9	Aβ₄₀	r = − 0.722 (− 0.937, − 0.111)	0.028	r (6) = − 0.759 (− 0.946, − 0.191)	0.029
NHWs	Controls	28	t-tau/Αβ₄₂	ρ = − 0.602 (− 0.796, − 0.296)	< 0.001	r (25) = − 0.573 (− 0.779, − 0.255)	0.002
			p-tau	r = − 0.435 (− 0.695, − 0.074)	0.021	r (25) = − 0.399 (− 0.672, − 0.031)	0.039
			t-tau	r = − 0.541 (− 0.761, − 0.210)	0.003	r (25) = − 0.521 (− 0.749, − 0.184)	0.005

Correlation analysis was performed using Pearson’s (r) correlation test or Spearman’s (ρ) rank coefficient. Partial correlations are shown as r (degrees of freedom) and were obtained after accounting for APOE genotype
CI Confidence interval, B/AAs Black/African-Americans, NHWs Non-Hispanic whites, Αβ₄₀, amyloid-β40 peptide, Αβ₄₂ amyloid-β42 peptide, t-tau Total tau, p-tau Tau phosphorylated at Thr181, apoE Apolipoprotein E

ISSN: 1758-9193